The clever thing about ForteBio's Octet was not simply that it watched molecules bind. It made the sample stand still and sent the sensor in for a dip.
The Minneapolis life-sciences supplier turned a catalog of repeat-purchase reagents into a $1.2 billion business. Its best lesson is not the pending $11.3 billion exit - it is how one expensive diagnostics detour forced the portfolio back toward tools that scale.